Darolutamide trials for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Q: How many trials study Darolutamide for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)?

3 recruiting trials study Darolutamide in trials listing Metastatic Hormone-sensitive Prostate Cancer (mHSPC) in our tracked data. This is not a statement that it treats the condition.

All Darolutamide trials · All Metastatic Hormone-sensitive Prostate Cancer (mHSPC) trials

Recruiting trials

Phase breakdown

Phase 1 2Phase 2 1Phase 3 1

Recruiting trials studying Darolutamide for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
NCT03903835 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 32 locations
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
NCT07140900 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 16 locations
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT07190300 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 31 locations

Common questions

How many trials study Darolutamide for Metastatic Hormone-sensitive Prostate Cancer (mHSPC)?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.